• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

Recombinant Human TIGIT protein (His Tag)

Species

Human

Purity

>95 %, SDS-PAGE

Tag

His Tag

Activity

EC50: 100-400 ng/mL

Cat no : Eg0749

Validation Data Gallery

  • Purity of Recombinant Human TIGIT was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

    Purity of Recombinant Human TIGIT was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

  • Immobilized Human TIGIT (His tag) at 2 μg/mL (100 μL/well) can bind Human CD155 (hFc tag, Myc tag, His tag) with a linear range of 100-400 ng/mL.

    Immobilized Human TIGIT (His tag) at 2 μg/mL (100 μL/well) can bind Human CD155 (hFc tag, Myc tag, His tag) with a linear range of 100-400 ng/mL.

Product Information

Purity >95 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity 
Immobilized Human TIGIT (His tag) at 2 μg/mL (100 μL/well) can bind Human CD155 (hFc tag, Myc tag, His tag) with a linear range of 100-400 ng/mL.
Expression HEK293-derived Human TIGIT protein Met22-Pro141 (Accession# Q495A1-1) with a His tag at the C-terminus.
GeneID 201633
Accession Q495A1-1
PredictedSize 13.9 kDa
SDS-PAGE 15-18 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

T cell immunoreceptor with Ig and ITIM domains(TIGIT), also named as V-set and immunoglobulin domain-containing protein 9 (VSIG9), V-set and transmembrane do-maincontaining protein 3 (VSTM3) and Washington University cell adhesion molecule (WUCAM), is a co-inhibitory molecule belonging to the immunoglobulin superfamily that was first discovered in 2009. It consists of an extracellular immunoglobulin variable (IgV) domain, a type I transmembrane domain and an intracellular domain with an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoglobulin tail tyrosine (ITT)-like motif. TIGIT is an inhibitory receptor expressed on several types of lymphocytes. Efficacy of antibody blockade of TIGIT in cancer immunotherapy is currently widely being investigated in both pre-clinical and clinical studies. In multiple cancers TIGIT is expressed on tumor-infiltrating cytotoxic T cells, helper T cells, regulatory T cells and NK cells, and its main ligand CD155 is expressed on tumor-infiltrating myeloid cells and upregulated on cancer cells, which contributes to local suppression of immune-surveillance.

References:

1.Qiu D, et al. (2022) Clin Exp Med Jun;23(2):165-174.
2.Boles KS, et al. (2009) Eur J Immunol 39(3):695–703. 
3.Levin SD, et al. (2011) Eur J Immunol 41(4):902–15. 
4.Harjunpää H, et al. (2020) Clin Exp Immunol 200(2):108–19.
5.Jin S, et al. (2022) Front. Oncol. Dec 20;12:1091782. 
6.Ge Z, et al. (2021) Front. Immunol. Jul 22;12:699895.